肠道微生态调节对重症颅脑损伤患者多器官功能的影响

注册号:

Registration number:

ChiCTR2000036916 

最近更新日期:

Date of Last Refreshed on:

2020-09-28 10:48:24 

注册时间:

Date of Registration:

2020-08-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

肠道微生态调节对重症颅脑损伤患者多器官功能的影响

Public title:

Effect on multiple organ function for patients with critical brain injury via gut microbiota regulation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肠道微生态调节对重症颅脑损伤患者多器官功能的影响

Scientific title:

Effect on multiple organ function for patients with critical brain injury via gut microbiota regulation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谭佳颖 

研究负责人:

谭佳颖 

Applicant:

Tan Jiaying 

Study leader:

Tan Jiaying 

申请注册联系人电话:

Applicant telephone:

+86 13761519057

研究负责人电话:

Study leader's
telephone:

+86 13761519057

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

tanjiaying@huashan.org.cn

研究负责人电子邮件:

Study leader's E-mail:

tanjiaying@huashan.org.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市乌鲁木齐中路12号

研究负责人通讯地址:

上海市乌鲁木齐中路12号

Applicant address:

12 Middle Urumqi Road, Shanghai, China

Study leader's address:

12 Middle Urumqi Road, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属华山医院

Applicant's institution:

Huashan Hospital, Fudan University

研究负责人所在单位:

复旦大学附属华山医院

Affiliation of the Leader:

Huashan Hospital, Fudan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2020)临审第(934)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属华山医院伦理审查委员会

Name of the ethic committee:

Ethics Review Committee of Huashan Hospital Affiliated to Fudan University (HIRB)

伦理委员会批准日期:

Date of approved by ethic committee:

2020-08-21 00:00:00

伦理委员会联系人:

邹和建

Contact Name of the ethic committee:

Zou Hejian

伦理委员会联系地址:

上海市乌鲁木齐中路12号

Contact Address of the ethic committee:

12 Middle Urumqi Road, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属华山医院

Primary sponsor:

Huashan Hospital, Fudan University

研究实施负责(组长)单位地址:

上海市乌鲁木齐中路12号

Primary sponsor's address:

12 Middle Urumqi Road, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院

具体地址:

乌鲁木齐中路12号

Institution
hospital:

Huashan Hospital, Fudan University

Address:

12 Middle Urumqi Road

经费或物资来源:

上海申康医院发展中心

Source(s) of funding:

Shanghai Shenkang Hospital Development Center

研究疾病:

重症颅脑损伤  

Target disease:

Critical brain injury

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察肠道微生态调节对重症颅脑损伤患者脑与脑外多器官功能的影响。  

Objectives of Study:

To observe the effect on brain and extrencephalic multiple organ function for patients with critical brain injury via gut microbiota regulation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 入ICU前24小时内接受过含膳食纤维全营养素肠内营养产品;
2. 已知存在炎症性肠病(克罗恩病或溃疡性结肠炎)的患者;
3. 正在接受化疗、放疗者;
4. 骨髓或器官移植者;
5. HIV阳性患者;
6. 怀孕或哺乳期女性患者;
7. 既往有半乳糖血症病史者;
8. 已知对试验用产品中任何一种成分过敏者,或研究者判断需要限制膳食纤维摄入者;
9. 其它研究者认为不适合参加本研究的患者。

Exclusion criteria:

1. Enteral nutrition products containing dietary fiber and whole nutrient were received within 24 hours before ICU admission;
2. Patients with known presence of inflammatory bowel disease (Crohn's disease or ulcerative colitis);
3. Patients who are undergoing chemotherapy and radiation;
4. Patients who recieved bone marrow or organ transplant;
5. HIV positivity;
6. Pregnant or lactating woman;
7. A history of galactosemia;
8. Patients who are known to be allergic to any of the ingredients in the test products or who have been identified by researchers as needing to limit their dietary fiber intake;
9. Other patients considered not suitable for this study by researchers.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2022-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-10-01 00:00:00 To 2021-09-30 00:00:00

干预措施:

Interventions:

组别:

试验组1

样本量:

63

Group:

Trial group 1

Sample size:

干预措施:

半乳甘露聚糖

干预措施代码:

Intervention:

PHGG

Intervention code:

组别:

试验组2

样本量:

63

Group:

Trial group 2

Sample size:

干预措施:

半乳甘露聚糖+酪酸梭菌活菌片

干预措施代码:

Intervention:

PHGG+Lostridium Butyricum

Intervention code:

组别:

试验组3

样本量:

63

Group:

Trial group 3

Sample size:

干预措施:

瑞素+酪酸梭菌活菌片

干预措施代码:

Intervention:

TP+Lostridium Butyricum

Intervention code:

组别:

对照组

样本量:

63

Group:

Control group

Sample size:

干预措施:

瑞素

干预措施代码:

Intervention:

TP

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院 

单位级别:

三级甲等 

Institution
hospital:

Huashan Hospital, Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肠道微生态改变情况

指标类型:

主要指标

Outcome:

Changes in gut microbiota

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

器官功能评价

指标类型:

主要指标

Outcome:

Organ function evaluation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

目标喂养量的达标率

指标类型:

次要指标

Outcome:

Targeted feeding rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU停留期间血糖

指标类型:

次要指标

Outcome:

Blood glucose during ICU stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠内营养支持10天前后血红蛋白、前白蛋白、股四头肌厚度(QMLT)的变化

指标类型:

次要指标

Outcome:

Changes of hemoglobin, prealbumin, and quadriceps femoris thickness (QMLT) before and after 10 days of enteral nutrition support

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

入住ICU后28天(含)内病死率

指标类型:

次要指标

Outcome:

28 days mortality after ICU admission

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Length of hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

Length of hospital stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住ICU时间

指标类型:

次要指标

Outcome:

Length of ICU stay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎症水平

指标类型:

次要指标

Outcome:

Inflammation levels

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机方案由统计学专家负责制定,STATA 16.0统计软件产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The random scheme was developed by statistical experts, and STATA 16.0 statistical software produces random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

开放试验

Blinding:

Open label

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

请补充原始数据共享方式和平台(例如Resman, http://www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the paper was published in attachment

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用EDC系统收集数据,在首例受试者入组前,建立eCRF,并经过测试后正式上线。由专人(如CRC)负责将CRF的数据录入EDC。 CRA负责SDV,数据管理员负责发出Queries。 在统计分析前,经研究者、数据管理员、统计师等多方统一后进行数据库锁定,再由数据管理员按照相关SOP进行数据导出、传输。 纸质CRF需妥善保存试验结束后5年。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC system,CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-08-25 22:34:00